Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. John Eric Deanfield,
Dr. Eva Lonn
See the press release:Munich, Germany – August 27 2012: A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites...Read more
Presenter: Eva Lonn | see Discussant report
List of Authors: Eva M. Lonn, MD, MSc, Jackie Bosch, MSc, Rafael Diaz, MD, Patricio Lopez-Jaramillo, MD, Ambady Ramachandran MD, Nicolae Hâncu, MD, PhD, Markolf Hanefeld, MD, Krum Henry, MBBS, PhD, Lars Ryden, MD, PhD, Sandra Smith, RDMS, Matthew J. McQueen, MD, PhD, Leanne Dyal, MSc, Salim Yusuf MD, DPhil, Hertzel C. Gerstein, MD, MSc, for the GRACE and ORIGIN Investigators.
Context:People with dysglycemia are at increased risk for atherosclerosis and cardiovascular (CV) events. Effects of basal insulin titrated to normalize fasting plasma glucose or with n-3 fatty acid supplements on atherosclerosis progression in this population are unknown.
Objective:To evaluate effects of insulin glargine and of n-3 fatty acid supplements on carotid intima media thickness (CIMT).Design, Setting and Participants: Randomized multicenter international 2-by-2 factorial design trial of 1184 people (mean age, 63years) with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes.
Interventions: Participants received open label insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) in addition to standard care or standard glycemic care alone and double-blind therapy with a 1-g capsule of ethyl esters of n–3 fatty acids or placebo.
Main Outcome Measures:The primary outcome was the annualized rate of change in maximum CIMT for 12 carotid sites. Secondary outcomes were the annualized rates of change in maximum CIMT for the common carotid artery and for the common carotid plus bifurcation sites. Baseline, followed by annual ultrasounds were obtained during a median follow-up of 4.9 years.
Results:Compared to standard care, insulin glargine reduced the primary CIMT outcome, but the difference was not statistically significant (difference =0.0030 ± 0.0021 mm/year; p=0.145) and significantly reduced the secondary CIMT outcomes (differences of 0.0033 ± 0.0017 mm/year; p=0.049 and 0.0045 ± 0.0021 mm/year; p=0.032, respectively). There were no differences in the primary and secondary outcomes between the n-3 fatty acid supplement and placebo groups.
Conclusions:In people with known CV disease and/or CV risk factors and dysglycemia insulin glargine used to target normoglycemia, modestly reduced CIMT progression, while daily supplementation with 1 g of n-3 fatty acid supplements, had no effect on CIMT progression.
Discussant: John Eric Deanfield | see Presenter abstract
707011 - 707012
Hot Line II: Late Breaking Trials on Interventions
© 2016 European Society of Cardiology. All rights reserved